1 alpha-hydroxyergocalciferol (doxercalciferol)

Subscribe to Selected New Research on 1 alpha-hydroxyergocalciferol

23 relevant articles (5 outcomes, 7 trials/studies) found for this Drug

Description: decrease of bone density caused by prednisolone was prevented by above cpd; decreases number of osteoclast areas in normal rats; RN given refers to (1alpha,3beta,5Z,7E,22E)-isomer

Also Known As:

doxercalciferol; 1alpha(OH)2D2; 1alpha-OHD2; 1alpha-hydroxyvitamin D2; Bone Care brand of 1 alpha-hydroxyergocalciferol; Draxis brand of 1 alpha-hydroxyergocalciferol; Hectorol; doxacalciferol

Relationship Network

Drug Context: Research Results

Polycyclic Compounds: 58

1 alpha-hydroxyergocalciferol: 23

Cholestanes

Sterols: 383

Ergocalciferols: 372

1 alpha-hydroxyergocalciferol: 23

Cholestenes

Ergocalciferols: 372

1 alpha-hydroxyergocalciferol: 23

1 alpha-hydroxyergocalciferol: 23

Experts

1.	Albert, Daniel M: 2 articles (09/2004 - 05/2002)
2.	Lokken, Janice M: 2 articles (09/2004 - 05/2002)
3.	Darjatmoko, Soesiawati R: 2 articles (09/2004 - 05/2002)
4.	Strugnell, Stephen A: 2 articles (09/2004 - 05/2002)
5.	Lindstrom, Mary J: 2 articles (09/2004 - 05/2002)
6.	Frazão, J M: 2 articles (03/2001 - 09/2000)
7.	Elangovan, L: 2 articles (03/2001 - 09/2000)
8.	Goodman, W G: 2 articles (03/2001 - 09/2000)
9.	Maung, H M: 2 articles (03/2001 - 09/2000)
10.	Levine, B S: 2 articles (03/2001 - 09/2000)

Related Diseases

1.	Secondary Hyperparathyroidism 05/01/2004 - "CONCLUSION: Doxercalciferol is safe and effective in controlling secondary hyperparathyroidism of patients with CKD stages 3 and 4." 01/01/1998 - "Intermittent oral 1alpha-hydroxyvitamin D2 is effective and safe for the suppression of secondary hyperparathyroidism in haemodialysis patients" 11/01/2006 - "STUDY SELECTION AND DATA EXTRACTION: All published clinical studies evaluating the safety and effectiveness of doxercalciferol in secondary hyperparathyroidism were reviewed, and anecdotal patient reports were also evaluated" 11/01/2006 - "OBJECTIVE: To review the pharmacology, pharmacokinetics, effectiveness, safety, and therapeutic considerations related to the use of doxercalciferol in the treatment of secondary hyperparathyroidism" 11/01/2006 - "Doxercalciferol treatment of secondary hyperparathyroidism." Get all the results and reference details, order at left...
2.	Hypercalcemia (Milk Alkali Syndrome) 12/01/2001 - "Doxercalciferol is also effective in lowering parathyroid hormone (PTH), though hypercalcemia in hyperphosphatemic episodes occurred relatively frequently during the clinical studies" 05/01/2006 - "The vitamin D analog 19-Nor-1,25(OH)2-vitamin D2 (paricalcitol) and the prohormone 1alpha-OH-vitamin D2 (doxercalciferol) have been proposed as alternatives which may cause less hypercalcemia and elevated Ca x P, while still suppressing PTH" 11/01/2006 - "CONCLUSIONS: Doxercalciferol is approved for and effective in the treatment of secondary hyperparathyroidism related to CKD, both before and during dialysis, but has not demonstrated a lower incidence of hypercalcemia and/or hyperphosphatemia in relation to other vitamin D therapies" Get all the results and reference details, order at left...
3.	Hyperphosphatemia 11/01/2006 - "CONCLUSIONS: Doxercalciferol is approved for and effective in the treatment of secondary hyperparathyroidism related to CKD, both before and during dialysis, but has not demonstrated a lower incidence of hypercalcemia and/or hyperphosphatemia in relation to other vitamin D therapies" Get all the results and reference details, order at left...
4.	Kidney Diseases (Kidney Disease) 05/01/2004 - "Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4." 11/01/2006 - "DATA SYNTHESIS: Doxercalciferol effectively reduces parathyroid hormone levels in patients with chronic kidney disease (CKD)" 10/01/2008 - "AIMS: Doxercalciferol and paricalcitol are used to treat hyperparathyroidism in chronic kidney disease" 11/01/2001 - "Two vitamin D analogs are available in this country for the control of hyperparathyroidism in the setting of advanced kidney disease, and include 19-nor-1,25-dihydroxyvitamin D(2) (paricalcitol), and more recently, 1-alpha-hydroxyvitamin D(2) (doxercalciferol)" 06/01/2003 - "This paper reviews randomized controlled trials and other reported data on the use of the active vitamin D sterols, such as calcitriol, alfacalcidol, and doxercalciferol, in the management of secondary hyperparathyroidism in patients with mild-to-moderate renal insufficiency (stage 3 or 4 chronic kidney disease)" Get all the results and reference details, order at left...
5.	Renal Insufficiency 06/01/2003 - "This paper reviews randomized controlled trials and other reported data on the use of the active vitamin D sterols, such as calcitriol, alfacalcidol, and doxercalciferol, in the management of secondary hyperparathyroidism in patients with mild-to-moderate renal insufficiency (stage 3 or 4 chronic kidney disease)" Get all the results and reference details, order at left...
16 Diseases and 23 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Parathyroid Hormone (Parathormone)
2.	Vitamin D
3.	paricalcitol (Zemplar)
4.	Calcitriol (Calcijex)
5.	1-hydroxycholecalciferol (alfacalcidol)
6.	Sterols
7.	Phosphorus (Red Phosphorus)
8.	maxacalcitol
9.	1 alpha-hydroxyergocalciferol (doxercalciferol)
10.	hydroxide ion
21 Drugs and Important Bio-Agents and 16 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Heterologous Transplantation (Xenotransplantation)
2.	Renal Dialysis (Hemodialysis)
3.	Parathyroidectomy
4.	Peritoneal Dialysis
4 Therapies and Procedures and 5 more articles analyzed in the Research Interface, order at left...

Research Interface Subscription

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Searches
2 clicks from Disease to Drug to Evidence
Trial references
All the Positive Outcomes
Drug and Therapy searches
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface Subscription

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>